Elutia (Elutia) LT-Debt-to-Total-Asset : 0.47 (As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Elutia LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Elutia's long-term debt to total assests ratio for the quarter that ended in Dec. 2023 was 0.47.

Elutia's long-term debt to total assets ratio increased from Dec. 2022 (0.35) to Dec. 2023 (0.47). It may suggest that Elutia is progressively becoming more dependent on debt to grow their business.

Elutia LT-Debt-to-Total-Asset Historical Data

The historical data trend for Elutia's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Elutia LT-Debt-to-Total-Asset Chart

Elutia Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.44

0.22

0.16

0.35

0.47

Elutia Quarterly Data
	Dec18	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.35	0.42	0.49	0.46	0.47

Elutia LT-Debt-to-Total-Asset Calculation

Elutia's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (A: Dec. 2023 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2023 )	/	Total Assets (A: Dec. 2023 )
	=	20.356	/	43.428
	=	0.47

Elutia's Long-Term Debt to Total Asset Ratio for the quarter that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (Q: Dec. 2023 )	=	Long-Term Debt & Capital Lease Obligation (Q: Dec. 2023 )	/	Total Assets (Q: Dec. 2023 )
	=	20.356	/	43.428
	=	0.47

Elutia (NAS:ELUT) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Elutia LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Elutia's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Elutia (Elutia) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Elutia Inc (NAS:ELUT) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

12510 Prosperity Drive, Suite 370, Silver Spring, MD, USA, 20904

Website

https://www.aziyo.com

Elutia Inc Formerly Aziyo Biologics Inc is a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, concentrating on patients receiving implantable medical devices. The company's segments include Device Protection, Women's Health, Orthobiologics, and Cardiovascular. It generates maximum revenue from the Orthobiologics segment. The products of the company are targeted to address unmet clinical needs with the goal of promoting healthy tissue formation and avoiding complications associated with medical device implants, such as scar-tissue formation, capsular contraction, erosion, migration, non-union of implants and implant rejection.

Executives

Elutia Pipe Investment, Lp	10 percent owner	36 CHURCH LANE, WESTPORT CT 06880
Birchview Fund Llc	10 percent owner	688 PINE STREET, BURLINGTON VT 05401
Thomas Englese	officer: Chief Commercial Officer	C/O AZIYO BIOLOGICS, INC., 12510 PROSPERITY DRIVE, SUITE 370, SILVER SPRING MD 20904
David Colpman	director	452 FIFTH AVENUE, NEW YORK NY 10018
Brigid Makes	director	20245 SW 95TH AVENUE, TUALATIN OR 97062
Matthew Ferguson	officer: Chief Financial Officer	C/O FOXHOLLOW TECHNOLOGIES, INC., 740 BAY ROAD, REDWOOD CITY CA 94063
Highcape Partners Gp Ii, Llc	10 percent owner	36 CHURCH LANE, WESTPORT CT 06880
Highcape Partners Gp Ii, L.p.	10 percent owner	36 CHURCH LANE, WESTPORT CT 06880
Highcape Partners Qp Ii, L.p.	10 percent owner	36 CHURCH LANE, WESTPORT CT 06880
Highcape Partners Ii, L.p.	10 percent owner	36 CHURCH LANE, WESTPORT CT 06880
Highcape Capital, L.p.	10 percent owner	36 CHURCH LANE, WESTPORT CT 06880
Michelle Leroux Williams	officer: Chief Scientific Officer	C/O AZIYO BIOLOGICS, INC., 12510 PROSPERITY DRIVE, SUITE 370, SILVER SPRINT MD 20904
Matthew Strobeck	10 percent owner	C/O METABOLIX, INC., 21 ERIE STREET, CAMBRIDGE MA 02139
Birchview Capital, Lp	10 percent owner	688 PINE STREET, SUITE D, C/O BIRCHVIEW CAPITAL, BURLINGTON VT 05401
Peter G Edwards	officer: GENERAL COUNSEL	C/O BAXALTA INCORPORATED, 1200 LAKESIDE DRIVE, BANNOCKBURN IL 60015